指南与共识前列腺癌

局限性前列腺癌局灶治疗与部分腺体消融后的标准化命名与监测方法:国际多学科共识

Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
指南 / 共识 · Eur Urol · 2020-06-10

BACKGROUND: Focal therapy (FT) and partial gland ablation (PGA) are quickly adopted by urologists and radiologists as an option for the management of localized prostate cancer.…

要点

  • 推荐使用标准化命名描述局灶治疗和部分腺体消融技术。
  • 术后PSA第1年每3个月、之后每6个月检测,尽管其不是治疗失败的可靠标志。
  • MRI首选,术后6和18个月进行;6-12个月行12针系统穿刺加治疗区靶向穿刺。

核心结论

  • 专家组推荐使用所提出的命名和随访方案,以生成可靠数据支持FT作为选择性局限性前列腺癌患者标准治疗更广泛实施。

研究设计与样本

  • 国际多学科共识研究,通过文献回顾确定争议话题,进行三轮在线问卷和面对面会议,共识标准为80%同意率。

主要发现

  • 专家提出用于消融手术的标准化命名。
  • FT/PGA后应进行PSA、影像、活检和功能结局评估以评估治疗结果。
  • PSA虽非治疗失败的可靠标志,但建议第1年每3个月、之后每6个月检测。
  • MRI是首选影像模态,应在治疗后6和18个月进行。
  • 治疗后6-12个月应进行系统12针经直肠超声引导活检联合治疗区靶向活检。

关键数值与推荐

  • 共识定义为80%同意率。
  • PSA检测频率:第1年每3个月,之后每6个月。
  • MRI时间点:治疗后6和18个月。
  • 活检时间:治疗后6-12个月,系统12针经直肠超声引导联合治疗区靶向活检。
  • 功能结局评估:治疗后3-6个月首次,直至稳定。

临床怎么用

  • 采用标准化命名记录消融手术。
  • 按推荐时间点进行PSA、MRI、活检和功能评估随访。
  • 使用统一方案生成可靠数据,支持FT在选择性患者中的更广泛应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Focal therapy (FT) and partial gland ablation (PGA) are quickly adopted by urologists and radiologists as an option for the management of localized prostate cancer. OBJECTIVE: To find consensus on a standardized nomenclature and to define a follow-up guideline after FT and PGA for localized prostate cancer in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: A review of the literature identified controversial topics in the field of FT. Online questionnaires were distributed to experts during three rounds, with the goal to achieve consensus on debated topics. The consensus project was concluded with a face-to-face meeting in which final conclusions were formulated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Controlled feedback of responses of previous rounds were summarized and returned to the participants allowing them to re-evaluate their decisions. The level of agreement to achieve consensus on a topic was set at 80%. RESULTS AND LIMITATIONS: Sixty-five experts participated in this interdisciplinary consensus study (72% urologists; 28% radiologists). The experts propose the use of the herein standardized nomenclature for ablative procedures. After FT/PGA, the following tests should be performed to assess treatment outcomes: prostate-specific antigen (PSA), imaging, biopsies, and functional outcome assessment. Although not a reliable marker for treatment failure, PSA should be measured every 3 mo in the 1st year and every 6 mo thereafter. Magnetic resonance imaging is the preferred image modality and should be performed at 6 and 18 mo after treatment. A systematic 12-core transrectal ultrasound-guided biopsy combined with a targeted biopsy of the treated area should be performed 6-12 mo after treatment. Functional outcomes should be obtained 3-6 mo after treatment for the first time and until stability is attained. CONCLUSIONS: The panel recommends the use of the proposed nomenclature and follow-up protocols to generate reliable data supporting a broader implementation of FT as a standard of care for select patients with localized prostate cancer. PATIENT SUMMARY: In this report, we present expert opinion on the use of a standardized nomenclature, and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lebastchi AH, George AK, Polascik TJ, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol. 2020. PMID: 32532513. doi:10.1016/j.eururo.2020.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。